HSCS news

Fortitude Mining appointed Jaime Leverton to lead the company prior to its business combination with HeartSciences, resulting in a leadership transition. Leverton's appointment will continue post-merger as the mining platform moves toward a public listing.

HeartSciences Inc. reported fiscal first quarter results and noted progress on a proposed business combination with mining operator Fortitude, aimed for a Q4 2026 close. The company also launched commercial efforts for its MyoVista Insights platform.

Fortitude delivered $20.9 million in Q2 revenue and $8.5 million in adjusted EBITDA, highlighting operational efficiency as it coordinates a merger with medical technology company HeartSciences.

Fortitude Mining purchased $1M in HeartSciences shares at a 22% premium; the share purchase does not impact the pending business combination exchange ratio.

HeartSciences announced the filing of a preliminary proxy statement for a business combination with Fortitude Mining Holdings. The company also reported that the MyoVista wavECG device was submitted to the FDA while fiscal 2026 financial results were disclosed.

HeartSciences filed its fiscal year 2026 Form 10-K and intends to file a preliminary proxy statement shortly regarding a proposed business combination with Fortitude Mining. The company noted this represents a significant opportunity for shareholders.

HeartSciences and Andrew Simpson amended their employment agreement to modify the definition of constructive termination, specifically linking it to the Merger Agreement. This update clarifies severance claims in the event of a potential business combination.